Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs linagliptin for albuminuria in diabetic nephropathy
IRCT20200722048176N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin and linagliptin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Change in albuminuria. Started Sep 2020; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20200722048176N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200722048176N1.